The protein GIT1 appears to protect against breast tumor growth and can be linked to a better prognosis in breast cancer patients, according to findings from researchers at Karolinska Institute in Sweden. Their study results, published this week in Nature Communications, may contribute to development of new therapies for difficult-to-treat forms…

For the first time, researchers from the Vall d’Hebron Institute of Oncology’s (VHIO) Models of Cancer Therapies Group (Vall d’Hebron Barcelona Hospital Campus), and VHIO-born spin-off Peptomyc, have shown in a new mouse study that MYC inhibition is anti-metastatic in breast cancer. The researchers demonstrated how MYC inhibition by Omomyc…

The FDA has placed a partial clinical hold on five clinical trials—of which three are Phase III pivotal studies—by Gilead Sciences assessing its combination of magrolimab plus Vidaza (zacitidine) in various blood cancers, the company has acknowledged. Gilead said the FDA acted after the agency raised concerns over “an apparent…

Increasing scientific evidence supports the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies, and scientists headed by a team at Baylor College of Medicine have now reported that MAPK4 may play an important role in triple-negative breast cancer (TNBC). Analyzing public genomic datasets, the researchers…

Researchers have identified a metabolic enzyme and pathway in triple-negative breast cancer (TNBC) patients that they hope could serve as a biomarker to select patients for targeted therapy, including one drug, CPI-613, currently in trials for other cancers. Specifically, they found that high expression of dihydrolipoamide S-succinyltransferase (DLST), a tricarboxylic…

A lack of immune cells in the vicinity of cancer cells, called immune exclusion, is known to predict poor patient outcomes in multiple cancers, including triple-negative breast cancer (TNBC). Now, researchers at George Washington School of Medicine and Health Sciences have identified a key molecule, discoidin domain receptor 1 (DDR1), that…

Researchers at CU Cancer Center led by Diana Cittelly, Ph.D., report in the journal Clinical Cancer Research a potential new treatment option for breast cancer that has spreads to the brain. The researchers investigated the role of interleukin 13 receptor alpha 2 (IL13Ra2), a protein that is found in increased rates…

Researchers at Case Comprehensive Cancer Center uncovered a potentially important role for the protein-coding gene, MYO10, in regulating genomic instability, and in tumor development and immune therapy response. Their findings suggest that levels of MYO10 may indicate which breast cancers are likely susceptible to immune checkpoint blockade (ICB). The team’s…

Triple-negative breast cancer (TNBC) is notoriously difficult to treat because it lacks the receptors for estrogen, progesterone, and the growth factor HER2, all three of which can be targeted with effective cancer therapies. Standard chemotherapy regimens provide limited benefit against TNBC, and patients with metastatic disease have a poor prognosis…

A new study from researchers at the Mayo Clinic Cancer Center and collaborators from the CARRIERS consortium suggests that women over 65 with breast cancer could benefit from hereditary cancer genetic testing. These results, the researchers say, could affect further diagnostic testing, prevention, and treatment. The study was published in…

RNA-binding proteins may represent a new class of drug target for cancers—including triple-negative breast cancer (TNBC), a particularly difficult-to-treat cancer because it lacks most other molecular drug targets—according to new findings by researchers at University of California (UC), San Diego, School of Medicine. The researchers’ studies found that genetically deleting the…

A new mouse study reveals that low doses of a four-drug combination help prevent the spread of cancer without triggering drug resistance or recurrence by simultaneously targeting multiple pathways within a metastasis-promoting network. The findings are published in the journal eLife in a paper titled, “Limited inhibition of multiple nodes in a…

A pair of recent studies reinforces the idea that prolactin may be a major contributor to breast cancer development and could be a target for new drugs against multiple forms of the disease. VCU Massey Cancer Center researcher Charles Clevenger, MD, PhD, and his lab discovered a new, altered form…

Evading the immune system is the go-to survival strategy for cancer cells. One primary mechanism by which they do so is to downregulate their antigen presentation. New research shows that breast cancer cells bearing high levels of the MAL2 protein on their surfaces do just that. As a consequence, they…

Scientists are applying a common understanding of cancer cells—the fact that most cancer cells are aneuploid—to large-scale RNA-sequencing to better distinguish them from normal cells within a tumor. Known as CopyKAT (copy number karyotyping of aneuploid tumors), the tool serves as a computational method for detecting cancerous cells amidst large…